Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized controlled pilot study will be evaluating an app, MORT-PFPS app (ETH-01K), owned by EverEx, Inc., to examine safety and effectiveness in individuals with patellofemoral pain syndrome.
This randomized controlled pilot study will enroll 40 participants, where half will be randomly assigned to the app, MORT-PFPS (n = 20), and half will be assigned to treatment as usual (TAU) (n = 20), to examine safety and effectiveness in individuals with patellofemoral pain syndrome. All subjects will be followed up in the study for a total of 12 weeks, 8-week courses of treatment with additional 4-week observation. The app provides multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MORT-PFPS | Experimental | Participants randomly assigned to this arm will use the app, MORT-PFPS. |
|
| treatment as usual (TAU) | Active Comparator | Participants randomly assigned to this arm will receive their TAU only (no use of the app, MORT-PFPS). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MORT-PFPS app | Device | The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome. |
| Measure | Description | Time Frame |
|---|---|---|
| Usual pain severity assessed by the Numeric Rating Scale (NRS ) | The primary outcome being measure is differences in usual pain severity between groups after the intervention. NRS score was measured from 0 (no pain) to 10 (worst pain imaginable). | 8 weeks |
| Global rating of perceived recovery | The primary outcome being measure is differences in global rating of perceived recovery between groups after the intervention. Global rating of perceived recovery score was measured from 1 (very bad) to 7 (very good). | 8 weeks |
| Functional disability assessed by the Kujala Patellofemoral Scale | The primary outcome being measure is differences in functional disability between groups after the intervention. Kujala Patellofemoral Scale, also known as Anterior Knee Pain Scale, is a patient reported assessment of patellofemoral pain syndrome-specific functional limitations. It has 13 questions, and total score ranges from 0 to 100 (higher scores meaning better outcomes). | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Usual pain severity assessed by the Numeric Rating Scale (NRS) | The secondary outcome being measure is differences in usual pain severity between groups at 4 and 12 weeks. NRS score was measured from 0 (no pain) to 10 (worst pain imaginable). | 4, 12 weeks |
| Global rating of perceived recovery |
Not provided
Inclusion Criteria:
Male or female ≥ 19 and <50 years of age
Patients who have a history of anterior knee pain in one or both knees, persisting for longer than 3months but not longer than 2 years
Patients who have pain provoked by squatting
Patients who have pain provoked by 2 or more following activities
Patients who signed a written informed consent form
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chong Bum Chang, Dr. | Seoul National University Bundang Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Bundang Hospital | Seongnam-si | Gyeonggi-do | 13620 | South Korea | ||
| Seoul Metropolitan Government-Seoul National University Boramae Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41105952 | Derived | Lee S, Yoon C, Choi CH, Park TH, Yang SJ, Cha HR, Kim TW, Park JH, Chang MJ, Chang CB. Efficacy of a Mobile Multidisciplinary Digital Therapeutics App for Patellofemoral Pain: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2025 Oct 17;13:e69627. doi: 10.2196/69627. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D046788 | Patellofemoral Pain Syndrome |
| ID | Term |
|---|---|
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Single site, randomized controlled trial research study
Not provided
Not provided
Not provided
Not provided
| treatment as usual (TAU) | Other | In the control group, psychoeducation is delivered and self-exercise is recommended. |
|
The secondary outcome being measure is differences in global rating of perceived recovery between groups at 4 and 12 weeks. Global rating of perceived recovery score was measured from 1 (very bad) to 7 (very good). |
| 4, 12 weeks |
| Functional disability assessed by the Kujala Patellofemoral Scale | The secondary outcome being measure is differences in functional disability between groups at 4 and 12 weeks. Kujala Patellofemoral Scale, also known as Anterior Knee Pain Scale, is a patient reported assessment of patellofemoral pain syndrome-specific functional limitations. It has 13 questions, and total score ranges from 0 to 100 (higher scores meaning better outcomes). | 4, 12 weeks |
| Worst pain severity, pain during specific activities (running, standing up from sitting, going up or down stairs, and sleeping) assessed by the Numeric Rating Scale (NRS) | The secondary outcome being measure is differences in worst pain severity, pain during specific activities between groups at 4, 8 and 12 weeks. NRS score was measured from 0 (no pain) to 10 (worst pain imaginable). | 4, 8, 12 weeks |
| Health-related quality of life assessed by EuroQol five-dimensional (EQ-5D) | The secondary outcome being measure is differences in health-related quality of life between groups at 4, 8 and 12 weeks. It measures five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with three possible answers for each dimension (1=no problem, 2=moderate problem, 3=severe problem). The instrument also includes a visual analogue scale, which is numbered from 0 (the worst health you can imagine) to 100 (the best health you can imagine). | 4, 8, 12 weeks |
| Changes of Knee strength | Flexion and extension strength of knee are measured using a Biodex isokinetic dynamometer (peak torque (Nm) and % decrease in torque). | 8, 12 weeks |
| Changes of hip abductor function | Hip abductor function is assessed by knee valgus angle during single leg squat (°). | 8, 12 weeks |
| Changes of usual pain severity, worst pain severity, pain during specific activities (running, standing up from sitting, going up or down stairs, and sleeping), assessed by the Numeric Rating Scale (NRS) | The secondary outcome being measure is differences in changes of usual pain severity, worst pain severity, pain during specific activities from baseline to 4, 8, and 12 weeks between groups. NRS score was measured from 0 (no pain) to 10 (worst pain imaginable). | 4, 8, 12 weeks |
| Changes of functional disability assessed by the Kujala Patellofemoral Scale | The secondary outcome being measure is differences in changes of functional disability from baseline to 4, 8, and 12 weeks between groups. Kujala Patellofemoral Scale, also known as Anterior Knee Pain Scale, is a patient reported assessment of patellofemoral pain syndrome-specific functional limitations. It has 13 questions, and total score ranges from 0 to 100 (higher scores meaning better outcomes). | 4, 8, 12 weeks |
| Changes of health-related quality of life assessed by EuroQol five-dimensional (EQ-5D) [ Time Frame: 4, 8, 12 weeks ] | The secondary outcome being measure is differences in changes of health-related quality of life from baseline to 4, 8, and 12 weeks between groups. It measures five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with three possible answers for each dimension (1=no problem, 2=moderate problem, 3=severe problem). The instrument also includes a visual analogue scale, which is numbered from 0 (the worst health you can imagine) to 100 (the best health you can imagine). | 4, 8, 12 weeks |
| Assessment of mental health symptoms specific to depression as assessed by the Patient Health Questionnaire-9 (PHQ-9) | Differences in mental health symptoms between groups at 8, 12 weeks. The Patient Health Questionnaire-9 (PHQ-9) total score for the nine items ranges from 0 to 27 (higher scores indicating greater severity of depression). | 8, 12 weeks |
| Assessment of catastrophic thinking measured by Pain Catastrophizing Scale (PCS) | Differences in levels of catastrophic thinking between groups at 8, 12 weeks. The Pain Catastrophizing Scale (PCS) is a 13-item scale, with a total range of 0 to 52 (higher scores indicating higher amounts of pain catastrophizing). | 8, 12 weeks |
| Assessment of fear avoidance behaviours measured by Fear-Avoidance Beliefs Questionnaire (FABQ) | Differences in fear avoidance behaviours between groups at 8, 12 weeks. The Fear-Avoidance Beliefs Questionnaire (FABQ) is a 16-item scale, with a total range of 0 to 96 (higher scores indicating higher amounts of fear avoidance behaviours). | 8, 12 weeks |
| Use of rescue medication | Differences in use of rescue medication between groups at 4, 8, 12 weeks. | 4, 8, 12 weeks |
| Assessment of retention in treatment | Differences in retention rates between groups at 4, 8 weeks. | 4, 8 weeks |
| Dongjak |
| Seoul |
| 07061 |
| South Korea |